Alpine Immune Sciences, Inc. ALPN
We take great care to ensure that the data presented and summarized in this overview for ALPINE IMMUNE SCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALPN
View all-
Decheng Capital LLC Menlo Park, CA8.32MShares$044.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.78MShares$02.76% of portfolio
-
Black Rock Inc. New York, NY3.58MShares$00.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.13MShares$06.52% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.08MShares$00.01% of portfolio
-
State Street Corp Boston, MA2.85MShares$00.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.71MShares$00.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.7MShares$06.16% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.68MShares$02.39% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.12MShares$03.15% of portfolio
Latest Institutional Activity in ALPN
Top Purchases
Top Sells
About ALPN
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Insider Transactions at ALPN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Christopher Peetz Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,900
-100.0%
|
-
|
|
May 20
2024
|
Robert E Conway Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
50,000
-100.0%
|
-
|
|
May 20
2024
|
Mitchell Gold Executive Chairman and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,245
-56.06%
|
-
|
|
May 20
2024
|
Stanford L Peng Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
344,163
-93.03%
|
-
|
|
May 20
2024
|
James Paul Rickey Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,961
-73.09%
|
-
|
|
May 20
2024
|
Remy Durand Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133,392
-88.31%
|
-
|
|
May 20
2024
|
Ulrich Martin Fuhs Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,120
-87.88%
|
-
|
|
May 18
2024
|
Peter A. Thompson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,680,496
-100.0%
|
-
|
|
May 18
2024
|
James N Topper Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,829,347
-100.0%
|
-
|
|
May 18
2024
|
Mitchell Gold Executive Chairman and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,627,157
-100.0%
|
-
|
|
May 18
2024
|
Xiangmin Cui Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,317,924
-100.0%
|
-
|
|
May 18
2024
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,680,496
-100.0%
|
-
|
|
May 08
2024
|
Remy Durand Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
95,288
+17.15%
|
$571,728
$6.36 P/Share
|
|
May 08
2024
|
Stanford L Peng Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
271,792
+12.88%
|
$1,358,960
$5.98 P/Share
|
|
May 08
2024
|
Ulrich Martin Fuhs Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,820
+43.11%
|
$273,840
$12.07 P/Share
|
|
May 08
2024
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,245
+10.81%
|
$92,715
$7.55 P/Share
|
|
May 07
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,761
+7.15%
|
$187,327
$7.8 P/Share
|
|
Apr 25
2024
|
James N Topper Director |
SELL
Open market or private sale
|
Indirect |
19
-0.0%
|
$1,216
$64.57 P/Share
|
|
Apr 25
2024
|
James N Topper Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,200,000
+29.78%
|
-
|
|
Jan 26
2024
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
117,764
-100.0%
|
$2,708,572
$23.66 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 4.11M shares |
|---|---|
| Open market or private purchase | 750K shares |
| Grant, award, or other acquisition | 206K shares |
| Exercise of conversion of derivative security | 883K shares |
| Open market or private sale | 3.59M shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 19.1M shares |
| Sale (or disposition) back to the issuer | 727K shares |
| Payment of exercise price or tax liability | 48.3K shares |